Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitravatinib in Combination With Nivolumab Versus Docetaxel in Advanced Non-Squamous NSCLC
NCT03906071Phase 3Terminated
- Sponsor
- Mirati Therapeutics
- Start
- Jul 2019
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of sitravatinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 arms), sponsored by Mirati Therapeutics. Primary endpoint: Overall Survival at 44 months. Started Jul 2019; status: terminated.
02
Drugs
sitravatinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03906071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03906071.